
Potential monoclonal antibody to prevent RSV enters human trials
Ark Biopharmaceutical (ArkBio) says it has successfully dosed all participants in a Phase I clinical study of AK0610, a fully human monoclonal antibody designed to prevent respiratory syncytial virus (RSV) infection. The treatment offers a potential a new option for preventing RSV infection for vulnerable infants susceptible… Read More
